BenevolentAI S.A.
BAI
ISIN LU2355630455 / Valor 112417726
BenevolentAI S.A.
UMushroom community rating:
About company
BenevolentAI S.A. is a pioneering entity in the intersection of artificial intelligence (AI) and biopharmaceuticals, focusing on the discovery and development of novel drugs. Leveraging its proprietary Benevolent Platform™, the company has successfully built a diverse pipeline of drug candidates. These candidates are distinguished by their potential to become either the best in their class or the first of their kind, indicating a significant emphasis on innovation and addressing unmet medical needs. The use of AI in drug discovery allows BenevolentAI to streamline the research process, potentially reducing the time and cost associated with bringing new therapies to market. While the company's specific therapeutic areas are not detailed in the provided source, the mention of a "rich drug pipeline" suggests a broad focus on developing treatments for a variety of diseases, positioning BenevolentAI at the forefront of technology-driven pharmaceutical research.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (10.11.2025):
For Q2 2023 (unaudited), BenevolentAI S.A. reported its latest financial results with modest revenue of £7.3m (excluding SBP) and continued strong investment in R&D. The figures reflect a mixed performance in which lower revenues from the AstraZeneca collaboration were partly offset by the new Merck partnership, alongside a significant improvement in the operating loss compared to similar figures reported in 2022.
Revenue Overview
BenevolentAI S.A. recorded revenue of £7.3m (exc. SBP) at 30 June 2023. The decrease linked to reduced income from the AstraZeneca collaboration was partially offset by a new Merck deal.
R&D Investment
The company reported an R&D spend of £60.3m in Q2 2023, up from £54.6m in 2022, underlining its continued commitment to advancing drug discovery and development through strategic collaborations.
Operating Loss Improvement
BenevolentAI S.A. saw its reported operating loss before changes to working capital narrow to £77.6m in Q2 2023, a notable improvement from the £197.0m loss recorded in 2022.
Cash Position
Normalised cash, cash equivalents, and short-term deposits stood at £56.5m at 30 June 2023 compared to £130.2m at the end of 2022, reflecting ongoing investments and operational activity during the period.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
102 M
Market cap (USD)
Daily traded volume (Shares)
0.423 / 0.38
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
